Amgen announces top-line results of Vectibix® (panitumumab)
7 May 2013 | By Amgen
Study meets primary endpoint of non-inferiority in monotherapy setting...
List view / Grid view
News
Novo Nordisk invests DKK 380 million in its Kalundborg plant
6 May 2013 | By Novo Nordisk
Novo Nordisk is investing an additional 380 million Danish kroner in its Kalundborg plant in Denmark...
Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in circulation
6 May 2013 | By Bristol-Myers Squibb Company
ARISTOTLE studied Eliquis vs. warfarin...
Boehringer Ingelheim joins Structural Genomics Consortium – for further research into uncurable diseases
6 May 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC)...
FDA approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin)
3 May 2013 | By Merck
LIPTRUZET approved for patients with primary or mixed hyperlipidemia, as an adjunct to diet when diet alone is not enough...
Funding boost for GSK’s open innovation research into diseases affecting the developing world
3 May 2013 | By GlaxoSmithKline
GlaxoSmithKline announced a funding injection of up to £5m from the Wellcome Trust...
Fluidigm to develop and supply a custom high-throughput prep system for HLA typing
3 May 2013 | By kdm communications limited
The new system will help the DKMS accelerate...
Bristol-Myers Squibb receives US FDA sNDA approval for use of SUSTIVA® (efavirenz)
3 May 2013 | By Bristol-Myers Squibb Company
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization
2 May 2013 | By Sanofi
A new commercial organization to better align with its business priorities...
Gilead reports interim data from Phase 2 LONESTAR study
2 May 2013 | By Gilead Sciences
Gilead Sciences announced plans to initiate a third Phase 3 clinical trial...
Bulgin’s Buccaneer® connectors now rated to IP69K
1 May 2013 | By kdm communications limited
The Buccaneer range of advanced waterproof power and data connectors has been independently rated to IP69K – DIN 40050-9
Merck announces new $15 billion share repurchase program
1 May 2013 | By Merck
Merck's board of directors has authorized additional purchases of up to $15 billion of Merck’s common stock for its treasury.
FDA approves ACTEMRA for children living with a rare form of arthritis
30 April 2013 | By Roche
Roche announced that the U.S. FDA has approved ACTEMRA...
Teva expands management team
29 April 2013 | By TEVA
Teva appoints Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer...
Merck & Co., Inc. and Pfizer enter worldwide collaboration agreement
29 April 2013 | By Merck
Agreement to develop and commercialize Ertugliflozin, an investigational medicine for type 2 diabetes...
